Get Live Data

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Roquefort Thera Share Price
  4. Roquefort Thera Share Regulatory News
  5. Update on Acquisition of Lyramid Limited

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

Roquefort Thera Information

Share Price Information for Roquefort Thera (ROQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.90
Bid: 4.80
Ask: 5.00
Change: 0.00 (0.00%)
Spread: 0.20 (4.167%)
Open: 4.90
High: 4.90
Low: 4.90
Prev. Close: 4.90
ROQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Acquisition of Lyramid Limited

12 Nov 2021 07:33

RNS Number : 2223S
Roquefort Investments PLC
12 November 2021
 

12 November 2021

 

 

Roquefort Investments plc

("Roquefort Investments" or the "Company")

 

Update on Acquisition of Lyramid Limited

 

Roquefort Investments (LSE:ROQ), the London listed investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, is pleased to announce that it has commenced marketing to potential investors to fund the acquisition and pre-clinical drug development programme of Lyramid Limited, details of which were announced on 29 September 2021. A copy of the presentation is available on the Company's website at https://www.roquefortinvest.com/presentations

 

The Company looks forward to providing further updates in relation to the acquisition of Lyramid Limited as and when appropriate.

 

The Company's shares remain suspended from trading on the Main Market of the London Stock Exchange pending the publication of a Prospectus setting out full details of the potential transaction.

 

 

Enquiries:

 

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Joint Broker)

Christian Dennis

+44 (0)20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQBTBRTMTTBMLB
123
Date   Source Headline
15th Sep 202212:26 pmRNSNotice of Admission
13th Sep 202211:08 amRNSPublication of Prospectus
11th Aug 20227:00 amRNSPre-clinical Program & Transaction Update
20th Jul 20227:00 amRNSAppointment of Joint Broker
15th Jul 20227:00 amRNSCommencement of Trading on US OTCQB Venture Market
4th Jul 20224:57 pmRNSDirector/PDMR Shareholding
30th Jun 20224:38 pmRNSDirector/PDMR Shareholding
30th Jun 202210:30 amRNSResult of AGM
23rd Jun 20227:00 amRNSUpdate on Acquisition of Oncogeni and Placing
22nd Jun 20224:42 pmRNSIssue of Warrants
22nd Jun 202210:32 amRNSInvestor Presentation
22nd Jun 20229:05 amRNSSecond Price Monitoring Extn
22nd Jun 20229:00 amRNSPrice Monitoring Extension
22nd Jun 20227:00 amRNSProposed Acquisition of Oncogeni Limited & Placing
13th Jun 20227:00 amRNSNotice of AGM - Correction
7th Jun 20227:00 amRNSPre-clinical Update
7th Jun 20227:00 amRNSNotice of AGM
11th May 20227:00 amRNSAnnual Report & Financial Statements
20th Apr 20227:00 amRNSNon-Executive Director Appointment
5th Apr 20227:00 amRNSBoard Appointment
22nd Mar 20228:08 amRNSHolding(s) in Company
21st Mar 20229:34 amRNSInvestor Presentation
21st Mar 20227:00 amRNSPatent Filed – New Drug Class Targeting Midkine
8th Mar 20227:54 amRNSHolding(s) in Company
14th Feb 20227:00 amRNSAppointment of Strategic & Scientific Advisor
8th Feb 202211:35 amRNSHolding(s) in Company
28th Jan 20227:00 amRNSHolding(s) in Company
19th Jan 202212:56 pmRNSDirector/PDMR Shareholding
19th Jan 20228:39 amRNSHolding(s) in Company
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:51 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSPre-clinical Update
10th Jan 20228:00 amRNSPublication of New Research
31st Dec 20217:00 amRNSChange of Company Name
22nd Dec 20217:00 amRNSHolding(s) in Company
21st Dec 20219:06 amRNSSecond Price Monitoring Extn
21st Dec 20219:00 amRNSPrice Monitoring Extension
21st Dec 20217:00 amRNSAcquisition Completion, Admission & Voting Rights
16th Dec 20214:24 pmRNSPublication of Prospectus
13th Dec 20211:19 pmRNSResults of General Meeting
22nd Nov 20217:00 amRNSConditional Placing to Raise £3 Million
19th Nov 20217:00 amRNSCircular and Notice of General Meeting
18th Nov 20217:00 amRNSProposed Acquisition of Lyramid Pty Limited
12th Nov 20217:33 amRNSUpdate on Acquisition of Lyramid Limited
29th Oct 20212:01 pmRNSInterim Results to 30 June 2021
20th Oct 20217:00 amRNSBoard Changes
29th Sep 20217:34 amRNSReverse Takeover & Suspension of Trading
29th Sep 20217:30 amRNSSuspension - Roquefort Investments Plc
26th Aug 202112:42 pmRNSHolding(s) in Company
123

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.